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Introduction
The platelet-derived growth factor (PDGF) family contains 
five members found naturally in the body. These are AA 
homodimer, AB heterodimer, BB homodimer, CC homodi-
mer, and DD homodimer.1 PDGF-BB is a homodimer of 
two antiparallel B-chains covalently linked through two 
disulfide bonds. While these isoforms have different bind-
ing specificities to PDGF cell-surface receptors, PDGF-BB 
is considered the universal PDGF isoform because it can 
bind to all known PDGF receptors.2,3 PDGF-BB is a pri-
mary component of platelets released at sites of injury fol-
lowing platelet activation. PDGF-BB is chemotactic and 
mitogenic for cells of mesenchymal origin.2,3 Additionally, 
PDGF-BB is proangiogenic, upregulating vascular endothe-
lial growth factor (VEGF) to stimulate new capillary 
growth.2 Through these biological activities, PDGF-BB 
contributes to tissue repair.
The development of recombinant human PDGF-BB 
(rhPDGF-BB) for therapeutic purposes focused initially   
on soft tissue healing with Regranex® (developed by a sub-
sidiary of Johnson & Johnson New Brunswick, NJ, USA; 
now owned by HealthPoint Biotherapeutics Fort Worth, 
TX, USA). Later efforts concentrated on regeneration of 
periodontal bone with GEM 21S® (developed by 
BioMimetic Therapeutics, Inc., Franklin, TN, USA; now 
owned by Luitpold Pharmaceuticals, Inc, Shirley, NY, 
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USA). Nonclinical orthopedic studies, including fracture 
repair in models of impaired healing (geriatric/osteoporotic 
or diabetic),4,5 distraction osteogenesis,6 and spine fusion7 
demonstrated the efficacy of rhPDGF-BB in bone augmen-
tation and the foundation for development of clinical 
applications.8–12
Augment® Bone Graft (Augment) comprises an osteo-
conductive scaffold of β-tricalcium phosphate (β-TCP) and 
rhPDGF-BB. rhPDGF-BB is a protein of approximately 
24.5 kDa produced using recombinant DNA technology in 
a Saccharomyces cerevisiae expression system. The two 
components are mixed prior to implantation. Augment is 
intended as an alternative to autologous bone graft (auto-
graft) in hindfoot or ankle joint fusion sparing the patient 
the morbidity of autograft harvest. The average dose of 
rhPDGF-BB administered in orthopedic clinical trials using 
Augment is 1.8 mg (6 cm3 of β-TCP + 6 mL of 0.3 mg/mL 
rhPDGF-BB); the maximum clinical dose is 2.7 mg (9 cm3 
of β-TCP + 9 mL of 0.3 mg/mL rhPDGF-BB).
Due to its biological activity, altered expression of 
PDGF-BB has been associated with concerns of potential 
tumor promotion.13,14 However, as discussed below, the 
emerging data appear to provide reassurance about the 
safety of rhPDGF-BB. This is, in part, due to the funda-
mental differences between the local single administration 
of rhPDGF-BB in a combination device such as GEM 21S 
or Agument and the continuous deregulated expression of 
PDGF-BB in certain cancers.
Here, we present the latest nonclinical studies and 
review the data on the safety of rhPDGF-BB.
Materials and methods
Testing was conducted in accordance with guidance from the 
International Organization for Standardization (ISO), 
International Conference on Harmonisation (ICH), and 
United States Pharmacopeia (USP). Animal studies were 
performed at facilities accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) under protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) review (Table 1). 
rhPDGF-BB was provided by BioMimetic Therapeutics, 
Inc. β-TCP granules were obtained from Cam Bioceramics 
(Leiden, The Netherlands).
Pharmacokinetics
Two studies were carried out to evaluate circulating levels 
of rhPDGF-BB administered as a single intravenous (IV) 
dose. In the first study, 48 Sprague Dawley rats were dis-
tributed into two groups that received a single IV dose of 
either 0.44 mg/kg rhPDGF-BB or 20 mM sodium acetate. 
Serum samples were collected at baseline, 1, 5, 10, and 20 
min and 1, 4, 8, 24, 48, 72, 96, and 168 h post dose (n = 6 
per group per time point). In the second study, eight beagle 
dogs were distributed into two groups that received a single 
IV bolus dose of either 1.0 mg/kg of rhPDGF-BB or 20 mM 
sodium acetate. Samples were collected at the same time 
points listed above (n = 4 per group per time point). For 
both studies, the concentration of rhPDGF-BB was deter-
mined by enzyme-linked immunosorbent assay (ELISA). 
Table 1.  Nonclinical safety studies
Study Results
Pharmacokinetics Rat
10 × maximum clinical dose
Pharmacokinetics of rhPDGF-BB in 
Sprague Dawley rats following intravenous 
administration
Cmax: 6161.2 ng/mL
Tmax: 1.0 min
CL: 17.5 mL/min/kg
Pharmacokinetics Dog
23 × maximum clinical dose
Pharmacokinetics study in male beagle dogs 
following single intravenous administration of 
rhPDGF-BB
Cmax: 14,603.8 ng/mL
Tmax: 1.0 min
CL: 423.3 mL/min/kg
Reproductive and developmental toxicity
210 × maximum clinical dose
rhPDGF-BB: an intravenous injection 
teratology study in the rats
No maternal toxicity
No fetal toxicity
Carcinogenicity and chronic toxicity
4 × maximum clinical dose
Evaluation of the chronic toxicity and 
carcinogenicity of rhPDGF-BB mixed with 
β-TCP (Augment® Bone Graft) implanted in a 
rat model
No carcinogenicity
No toxicity
Transient local reaction to implanted 
material observed in both groups
rhPDGF-BB: recombinant human platelet-derived growth factor-BB; β-TCP: β-tricalcium phosphate; Cmax: maximum concentration observed; Tmax: 
time point at which the maximum concentration was observed; CL: clearance.Solchaga et al.  3
Pharma  cokinetic analyses were performed using a   
noncompartmental module of WinNonlin® (Pharsight, 
Cary, NC, USA).
Reproductive and developmental toxicity
The potential toxicity of rhPDGF-BB was studied by daily 
IV administration in gravid rats over 21 days of gestation. 
Three groups of 22 female rats received single daily doses 
of vehicle control (20 mM sodium acetate, pH 6.0)   
or rhPDGF-BB at a dose of either 40 or 400 µg/kg/day via 
IV injection for 21 days. On day 21 of gestation, all rats 
were euthanized and a gross pathological examination was 
performed. The reproductive tract of each dam was dis-
sected, the ovaries were removed, and the corpora lutea 
were counted. The gravid uterus was weighed, the uterine 
contents were examined, and the number and position of 
live and dead fetuses were recorded. Each fetus was 
weighed and given a detailed external examination. 
Additional groups of six rats per group were included   
for toxicokinetic analysis at baseline and day 21. Serum 
rhPDGF-BB concentration and antibody formation against 
rhPDGF-BB were determined using ELISA.
Carcinogenicity and chronic toxicity
In all, 300 (150 male, 150 female) Sprague Dawley rats 
were distributed into three groups. β-TCP was combined 
with either 0.3 mg/mL of rhPDGF-BB (test) or sodium ace-
tate (control). Aliquots of 200 µL of test or control article 
were implanted adjacent to the femur, underneath the mus-
cle; the third group received sham surgery. Animals were 
euthanized after 30 (n = 10 per group per sex), 180 (n = 10 
per group per sex), or 365 days (n = 30 per group per sex). 
Macroscopic and microscopic evaluations of toxicity and 
tumor incidence were performed. Serum was collected for 
hematology and clinical chemistry determinations. Anti–
PDGF-BB antibody formation was evaluated by ELISA.
Results
Pharmacokinetics
In the rat study, with an average delivered dose of 440.5 µg/kg,  
the concentration of rhPDGF-BB in serum decreased 
between 5 min and 1 h. After 1 h, the serum levels of   
rhPDGF-BB were below the level of quantitation (<0.156 
ng/mL). The Tmax was observed at 1 min with a Cmax of 
6161.2 ng/mL. The Area under the curve from time 0 to 4 
hours AUC0–4 was 380.7 h × ng/mL, and the clearance was 
17.5 mL/min/kg (Table 1). Following administration of the 
1.06 mg/kg IV dose in the canine model, Cmax (14,603.8 ng/
mL) occurred 1 min post dose. Half-life was 0.92 h. Inferred 
Area under the curve AUCinf was 2504.4 h × ng/mL, and 
the clearance was 423.3 mL/min/kg (Table 1).
Reproductive and developmental toxicity
No treatment-related mortality or significant adverse effects 
were observed. Effects on body weight, body weight gains, 
and food consumption were unremarkable. The gross path-
ological assessment was unremarkable in all treatment 
groups. The uterine parameters assessed (i.e. pregnancy 
rate, number of corpora lutea, implantation sites, live and 
dead fetuses, sex ratio, resorptions, and pre- and postim-
plantation losses) were unaffected in all treatment groups. 
Fetal weights were unaffected by treatment. The incidence 
of litters and fetuses with major malformations was unaf-
fected by the treatment across all treatment groups. The 
incidence of minor external and visceral anomalies was 
unaffected by rhPDGF-BB. Rat plasma samples were 
assayed for rhPDGF-BB using an ELISA. The plasma lev-
els of rhPDGF-BB in all dams and fetuses were below the 
level of detection (<0.625 mg/mL). No anti–rhPDGF-BB 
antibodies were detected in the 45 samples tested except in 
one pretreatment sample of one of the dams.
Carcinogenicity and chronic toxicity
No treatment-related mortality or effects on the clinical 
condition of the rats were observed. No remarkable test 
article–related changes in the body weight or body weight 
gain were observed. No significant changes in urinalysis 
parameters across treatment groups and gender were 
observed. Similarly, no significant changes in bone marrow 
parameters across treatment groups and gender were 
observed. There were no test article–related microscopic 
findings on days 30, 180, or 365 of the study. On day 30, 
minimal foreign body granulomas containing material con-
sistent with surgical sutures were present at the implant site 
across groups. Minimal to mild granulation tissue was 
noted at the implant site in animals from the control and the 
test article groups on day 30, day 180, and day 365. Because 
this was observed in both groups, it was likely a local reac-
tion to the β-TCP. There were no test article–related neo-
plastic microscopic observations noted in either sex on day 
365. None of the animals treated with the test article were 
positive for anti–PDGF-BB antibodies.
Discussion
Nonclinical studies
The safety of rhPDGF-BB alone or in combination with β-
TCP has been demonstrated in a comprehensive battery of 
in vivo and in vitro studies. The test materials were not 
mutagenic, hemolytic, cytotoxic, pyrogenic, or allergenic, 
and there was no evidence of either local or systemic toxic-
ity.15,16 Repeated daily administration of rhPDGF-BB by IV 
injection throughout the gestation period did not have any 
adverse effect in the dams or their progeny. A 1-year toxic-
ity study demonstrated that implantation of rhPDGF-BB in 
combination with β-TCP did not elicit any adverse effects, 4  Journal of Tissue Engineering 3(1)
tumor formation, or untoward immune reaction against the 
device. These outcomes highlight the safety of Augment, 
which is an implantable combination product intended for a 
single local administration for orthopedic tissue repair.
Regulation of local and systemic availability 
and clearance
PDGF is released from platelets at sites of injury and has a 
localized stimulatory effect on the wound healing process. 
Intrinsic clearance mechanisms limit systemic availability 
and regulate the local activity of PDGF. The presence of a 
plasma PDGF–binding protein was described in 1984.17–19 
Characterization of the interaction of PDGF with   
plasma proteins determined that this plasma protein was   
α2-macroglobulin.18,19 The α2-macroglobulin is present in 
two forms: a native and a transformed conformation, which 
occurs after protease activation. The receptor-mediated 
effects of PDGF (chemotaxis and mitogenesis) are inhib-
ited by binding to α2-macroglobulin.17,18 Interaction with 
α2-macroglobulin also regulates the clearance of PDGF. 
PDGF binds preferentially to the conformationally trans-
formed α2-macroglobulin,20 leading to rapid clearance of 
the complex through the low-density-lipoprotein-receptor-
related protein (LRP) pathway.20,21 Bonner et al.22 proposed 
that native α2-macroglobulin binds PDGF, serving as a res-
ervoir of PDGF to be released in the healing environment 
(i.e. sites of injury with low pH) but keeps it sequestered 
from systemic exposure. The inflammatory response and 
presence of proteases in sites of injury increase the confor-
mationally transformed α2-macroglobulin leading to pref-
erential binding of PDGF and rapid clearance from the 
circulation.
The results of the in vivo studies using radio-labeled 
rhPDGF-BB (125I-rhPDGF-BB) demonstrated that 60% to 
70% of the locally administered rhPDGF-BB was released 
from the implantation site in the first 60 min, followed by 
a slower, sustained release over several days.16 An addi-
tional study to assess the pharmacokinetics differences 
between IV administration of 125I-rhPDGF-BB and intra-
muscular (IM) implantation of 125I-rhPDGF-BB combined 
with β-TCP determined that the systemic bioavailability 
was similar by both routes of administration.16 Two studies 
with nonlabeled rhPDGF-BB delivered via IV administra-
tion to rats and dogs corroborate the findings of the studies 
performed with isotope-labeled rhPDGF-BB. In these 
studies, determination of rhPDGF-BB levels in serum was 
performed by ELISA. The half-life, Tmax, Cmax, and clear-
ance were comparable to those reported in previous 
studies.16
Tumorigenic potential of PDGF-BB
PDGF-B shares sequence homology with the simian sar-
coma virus oncogene, v-sis, and its cellular counterpart, 
c-sis.23,24 Cellular transformation induced by viral infec-
tion by v-sis is through the constitutive expression of the 
protein.25 Nonclinical evaluations, in vitro and in vivo, 
have demonstrated that chronic, constitutive expression 
of  v-sis and PDGF-BB results in cellular transforma-
tion.25,26 Although these observations, combined with the 
identification of high levels of PDGF-BB and PDGF 
receptors in certain tumors,13,14 associate PDGF-BB with 
a potential cancer risk, there are critical differences 
between viral infection by v-sis and the single-time 
administration of rhPDGF-BB in Augment. Removal of 
v-sis or PDGF-BB stimulus (i.e. gene silencing, neutral-
izing antibodies, chemical inhibition) results in reversal 
of the transformation.27–30 This suggests that these tumors 
are PDGF-BB dependent, requiring continuous exposure 
to PDGF-BB to maintain their transformed state. 
Furthermore, these observations may reflect autocrine or 
paracrine stimulation of proliferation rather than deregu-
lation of the cell cycle that is the hallmark of transformed 
cells.31
Clinical experience with rhPDGF-BB
Although some apprehension has been voiced about the 
risk of cancer formation or promotion with the use of 
growth factors, data from clinical investigations do not 
support such concerns. For example, the final analysis of 
a large study on patients treated with a topical gel con-
taining rhPDGF-BB (Regranex) found no increased risk 
of cancer incidence or cancer mortality with administra-
tion of rhPDGF-BB.32 This is reinforced by the data from 
a multicenter, randomized, controlled clinical trial com-
paring  Augment and autograft (2:1 randomization 
scheme) with 414 study subjects and a 12-month follow-
up. Five cancer events were reported in this clinical trial: 
three in the Augment group and two in the autograft 
group (1.1% and 1.4% incidence, respectively); none of 
the tumors in the Augment group were at or near the site 
of implantation (Table 2). The cancer events from   
six additional clinical studies using rhPDGF-BB and   
β-TCP are listed in Table 2. The cancer incidence in   
rhPDGF-BB–treated subjects was 0.7% compared to 
1.3% in control subjects. None of the 605 patients treated   
with rhPDGF-BB in these seven clinical trials had any 
serious device-related adverse events, immunologic 
sequelae, or other negative reactions attributable to the 
product.
GEM 21S, which was approved by the Food and Drug 
Administration (FDA) periodontal bone regeneration, is 
essentially identical to Augment. Upon review of all the 
available information from more than 150,000 implanted 
units, only one potential cancer-related event has been 
reported. The only commercial use of Augment has been in 
Canada where the product was approved in 2009 for foot 
and ankle fusions. Between 2009 and 2011 there were over Solchaga et al.  5
200 kits of Augment sold without receipt of a single report 
of adverse events (including cancer).
Conclusion
The use of rhPDGF-BB and Augment has been evaluated 
for potential toxicity in a variety of studies without sugges-
tion of toxicity, carcinogenicity, or mutagenicity after a   
single administration as an implantable device/drug combi-
nation product. The biological activity of rhPDGF-BB is 
regulated by α2-macroglobulin resulting in brief systemic 
exposure and rapid elimination of the protein by normal 
metabolic routes. Data from multiple clinical trials with 
Augment and GEM 21S and use of GEM 21S in clinical 
practice indicate that cancer incidence is not increased with 
clinical application of rhPDGF-BB.
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